Aberdeen Group plc Raises Stock Holdings in Acadia Healthcare Company, Inc. $ACHC

Aberdeen Group plc raised its stake in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 24.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 431,753 shares of the company’s stock after purchasing an additional 83,636 shares during the period. Aberdeen Group plc owned 0.47% of Acadia Healthcare worth $10,690,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of ACHC. Abrams Bison Investments LLC raised its stake in shares of Acadia Healthcare by 96.7% during the 2nd quarter. Abrams Bison Investments LLC now owns 3,580,000 shares of the company’s stock worth $81,230,000 after acquiring an additional 1,760,000 shares in the last quarter. Amundi grew its holdings in Acadia Healthcare by 1,006,804.5% in the second quarter. Amundi now owns 896,145 shares of the company’s stock worth $20,782,000 after purchasing an additional 896,056 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Acadia Healthcare during the second quarter worth $11,401,000. Teca Partners LP purchased a new stake in shares of Acadia Healthcare during the 2nd quarter valued at $10,086,000. Finally, Bank of America Corp DE boosted its position in shares of Acadia Healthcare by 60.2% in the 2nd quarter. Bank of America Corp DE now owns 1,156,484 shares of the company’s stock worth $26,241,000 after purchasing an additional 434,382 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Acadia Healthcare in a research note on Wednesday, January 21st. Bank of America lowered Acadia Healthcare from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $21.50 to $13.00 in a research report on Wednesday, December 3rd. Cantor Fitzgerald set a $17.00 target price on Acadia Healthcare in a report on Wednesday, December 3rd. Jefferies Financial Group cut shares of Acadia Healthcare to a “hold” rating in a report on Thursday, January 22nd. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Acadia Healthcare from $33.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $18.62.

Acadia Healthcare Price Performance

Acadia Healthcare stock opened at $16.86 on Friday. The stock has a market cap of $1.56 billion, a P/E ratio of 14.41, a PEG ratio of 4.82 and a beta of 0.89. Acadia Healthcare Company, Inc. has a 12-month low of $11.43 and a 12-month high of $42.85. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.73. The company has a 50-day moving average price of $14.18 and a 200 day moving average price of $18.57.

Acadia Healthcare Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.